Allogene Therapeutics, Inc. (ALLO)

Over the past six months, Allogene Therapeutics' stock has experienced fluctuations. In early February 2026, the stock price increased, but decreased over the last 12 months. Several executives sold shares, often to cover tax obligations. Citizens upgraded Allogene's stock rating in January 2026. Allogene announced key clinical milestones for 2026. In November 2025, Allogene reported its Q3 2025 financial results, beating EPS expectations, but the stock fell post-earnings, with cash reserves extending into late 2027. In May 2025, Allogene laid off 28% of its workforce to extend its cash runway, following a previous reduction, and delayed milestones for its lymphoma and autoimmune trials. In February 2025, the stock surged despite profitability struggles.

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company, its products are not yet commercially available on a wide scale, therefore, traditional "demand seasonality" is not applicable. The company's focus is on the development and clinical testing of its therapies, rather than commercial sales.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing allogeneic T cell therapies for cancer and autoimmune diseases. The company specializes in "off-the-shelf" cell therapy products, including UCART19 for B-cell ALL, cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for renal cell carcinoma, ALLO-329 for autoimmune diseases, ALLO-715 and ALLO-605, and additional products targeting DLL3, Claudin 18.2, and FLT3. Allogene has collaboration agreements with companies such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc., and a strategic collaboration with The University of Texas MD Anderson Cancer Center.

Allogene Therapeutics, Inc. is headquartered in South San Francisco, California, and has expanded its clinical trials to include sites in Australia and South Korea.

Allogene Therapeutics' brand reputation has been shaped by operational challenges and scientific advancements. Layoffs and clinical trial delays could raise concerns, while positive clinical milestones and analyst upgrades suggest a renewed positive outlook. The combination of workforce reductions and clinical delays, alongside the promising nature of its therapeutic pipeline and recent positive analyst sentiment, likely creates a mixed perception.

Allogene Therapeutics, Inc. has a significant number of institutional owners and shareholders, with 281 institutional owners holding a total of 185,627,401 shares. Major institutional owners include Pfizer Inc., TPG GP A, Llc, BlackRock, Inc., Citadel Advisors Llc, SMCWX - SMALLCAP WORLD FUND INC Class A, Vanguard Group Inc., Primecap Management Co/ca/, Woodline Partners LP, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Frazier Life Sciences Management, L.P., and Pfizer Venture Investments LLC is a top institutional holder.